相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond
Joseph Rimando et al.
BLOOD (2023)
Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation
Yunsuk Choi et al.
CLINICAL TRANSPLANTATION (2021)
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
Benjamin Watkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
Andres R. Rettig et al.
ANNALS OF HEMATOLOGY (2021)
Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
Mohamed A. Kharfan-Dabaja et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy
Corrado Zuanelli Brambilla et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel
Francesca Bonifazi et al.
BONE MARROW TRANSPLANTATION (2020)
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
Alexandros Spyridonidis et al.
BONE MARROW TRANSPLANTATION (2020)
Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation
Ehud Even-Or et al.
PEDIATRIC TRANSPLANTATION (2020)
Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
Krzysztof Kalwak et al.
BONE MARROW TRANSPLANTATION (2020)
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
Dietrich Wilhelm Beelen et al.
LANCET HAEMATOLOGY (2020)
Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years
Ali Bazarbachi et al.
CLINICAL CANCER RESEARCH (2020)
Second allogeneic hematopoietic cell transplantation for relapse after first allografts
Boglarka Gyurkocza et al.
LEUKEMIA & LYMPHOMA (2019)
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Francesco Saraceni et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
Avichai Shimoni et al.
BLOOD CANCER JOURNAL (2019)
Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation
Robert Zeiser et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse
Mohamed A. Kharfan-Dabaja et al.
JAMA ONCOLOGY (2018)
Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia
Corina Schneidawind et al.
ANNALS OF HEMATOLOGY (2018)
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
S. K. Metzelder et al.
EUROPEAN JOURNAL OF CANCER (2017)
Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
Mohamad Sobh et al.
HAEMATOLOGICA (2017)
Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
Mohamad Sobh et al.
HAEMATOLOGICA (2017)
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial
Irwin Walker et al.
LANCET ONCOLOGY (2016)
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT
T. Ruutu et al.
BONE MARROW TRANSPLANTATION (2015)
Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ≥ 10 years
G. Andreola et al.
BONE MARROW TRANSPLANTATION (2015)
Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change
Maximilian Christopeit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Eneida R. Nemecek et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Juergen Finke et al.
LANCET ONCOLOGY (2009)
Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation.
Luca Vago et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major
Maria Ester Bernardo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Thiotepa-based reduced intensity conditioning regimen: A 10 year followup
A. Bacigalupo et al.
BONE MARROW TRANSPLANTATION (2007)
Donor lymphocyte infusion in the treatment of first Hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia:: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party
Christoph Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood
B. Strahm et al.
BONE MARROW TRANSPLANTATION (2007)
Treosulfan and fludarabine:: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation
J Casper et al.
BLOOD (2004)
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant
M Eapen et al.
BONE MARROW TRANSPLANTATION (2004)
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies
EP Alessandrino et al.
BONE MARROW TRANSPLANTATION (2004)
分享论文
